Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S269100
Reexamination Certificate
active
07112595
ABSTRACT:
The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
REFERENCES:
patent: 3647809 (1972-03-01), Reiter et al.
patent: 3910940 (1975-10-01), Naranyan
patent: 4003909 (1977-01-01), Narayanan et al.
patent: 4022901 (1977-05-01), Narayanan et al.
patent: 4135910 (1979-01-01), Howe
patent: 5554630 (1996-09-01), Teuber et al.
patent: 5622976 (1997-04-01), Takasugi et al.
patent: 5750470 (1998-05-01), Morimoto et al.
patent: 1 149 011 (1963-05-01), None
patent: 2426878 (1976-01-01), None
patent: WO 94/22846 (1994-10-01), None
patent: WO 94/22846 (1994-10-01), None
patent: WO-95/32965 (1995-12-01), None
patent: WO 96/33194 (1996-10-01), None
patent: WO 97/03967 (1997-02-01), None
patent: WO 97/0396706096 (1997-02-01), None
patent: WO 98 17652 (1998-04-01), None
patent: WO 98/57969 (1998-12-01), None
patent: WO 99 02497 (1999-01-01), None
patent: WO 99/26927 (1999-06-01), None
patent: WO 01 12627 (2001-02-01), None
C. Montoliu et al., “Activation of the Metabotropic Glutamate Receptor mGluR5 Prevents Glutamate Toxicity in Primary Cultures of Cerebellar Neurons”, The Journal of Pharmacology and Experimental Therapeutics, May 2, 1997; pp. 643-647; vol. 281; The American Society of Pharmacology and Experimental Therapeutics; USA.
Ksasovitskij et al., Chemical Abstracts, vol. 123, No. 22, Abstract 299726w,608h, p. 447, Nov. 27, 1995.
Yurugi et al., Chemical Pharmaceutical Bulletin, vol. 21, No. 8, pp. 1641-1650, 1973.
William W. Paudler et al., “The Conversion of Imidazo[1,5-a]pyridines into3-(2-Pyridyl)-1,2,4-oxadiazoles”, Conversion of Imadazopyridines into Pyridyloxadiazoles, Aug. 1967, pp. 2430-2433; vol. 32; USA.
T. Ross Kelly et al., “Total Synthesis of Dimethyl Sulfomycinamate”, Tetrahedron Letters, 1995; pp. 5319-5322, vol. 36, No. 30, Elsevier Science Ltd. UK.
Wei Huang et al., “A Novel Improved Procedure for the Synthesis of Oxazoles”, Tetrahedron; 1996; pp. 10131-10136, vol. 52, No. 30; Elsevier Science Ltd., UK.
Mark A. Massa et al., Synthesis of Novel Substituted Pyridines as Inhibitors of Endothelin Converting Enzyme-1 (ECE-1); Bioorganic & Medicinal Chemistry Letters; 1998; pp. 2117-2122, vol. 8, Elsevier Science Ltd., UK.
Luciano Vio et al., “Note-low antihypertensive activity”, Journal; 5807502; EN; 321; 1988; pp. 713-717; Beilstein Instiut zur Foerderung der Chimischen Wissenschaften; Weinheim Germany.
Helene Perrier, et al., “Substituted Furans as Inhibitors of the PDE4 Enzyme”, Biorganic & Medicianl Chemistry Letters; 1999; pp. 323-326, vol. 9, Elsevier Science Ltd. UK.
Edward E. Glover et al. “The Nitration of Imidazo[1,5-a] pyridines” J of the Chem. Soc., Perkins I, 1980, pp. 959-961.
Robert K. Howe et al., “Nitrite Oxide Cycloaddition Routes to 2-(Isoxazolyl)-benzoates and 2-(1,2,4-Oxadiazol-3-yl)benzoates”, J. of Het. Chem., vol. 19, 1982, pp. 721-726.
Beilstein, XFire, CAS Registry No. 65004-22-0, 1988.
S. Robev, Doklady Bolgarskoi Akademil Nauk (1977), 30(7); pp. 1031-1034.
Arora Jalaj
Edwards Louise
Egle Ian
Isaac Methvin
McLeod Donald
Astrazeneca AB
Birch & Stewart Kolasch & Birch, LLP
Davis Zinna N.
NPS Pharmaceuticals Inc.
LandOfFree
Heteropolycyclic compounds and their use as metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteropolycyclic compounds and their use as metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteropolycyclic compounds and their use as metabotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3599072